n (% )
Gender
  Female 2 (6.9)
Male 27 (93.1)
Median of age (Q1-Q3) years 39 (32.5 - 44)
Tobacco consumption
  Yes 12 (41.4)
  No 17 (58.6)
Alcohol consumption
  Yes 13 (44.8)
  No 16 (55.2)
Transmission category
  MSM 25 (86.2)
Heterosexual 4 (13.8)
HAART
  Yes 26 (89.6)
Type of HAART  
  NRTIs + NNRTIs 13 (50.0)
NRTIs + PIs 10 (38.5)
Others* 3 (11.5)
Median HAART use (Q1-Q3) months   16.5 (Q1-Q3: 4.2-50.5)
CD4+ cells/mm3
  ≤ 200 10 (34.5)
201-499 14 (48.3)
≥ 500 5 (17.2)
Median  CD4+ (Q1-Q3) cells/mm3 243 (169-455.5)
Undetectable viral load 19 (65.5)
Median of viral load (Q1-Q3) log10 3.80 (2.76-4.58)
Q1-Q3=Interquartile Interval; MSM: men who have sex with men. HAART: Highly Active Antiretroviral Therapy; NRTIs: Nucleoside Reverse Transcriptase Inhibitors; NNRTIs: Non-Nucleoside Reverse transcriptase inhibitors; PIs=protease inhibitors. *One patient with NNRTIs+PIs; one patient with NRTIs+NNRTIs+PIs; one patient with four NRTIs.
Table 1: Demographic and clinical characteristics in 29 HIV/AIDS infected individuals with HPV-OL.
Goto home»